The National Comprehensive Cancer Network (NCCN) has published a new NCCN Guidelines for Patients: Immunotherapy Side Effects focused on chimeric antigen receptor (CAR) T-cell therapy. This is book two in a series that includes another book on irAEs focused on immune checkpoint inhibitors.Read more
UCLA researchers and colleagues have received a $13.65 million grant from the National Institutes of Health to investigate and further develop an immunotherapy known as CAR T, which uses genetically modified stem cells to target and destroy HIV.
The David and Etta Jonas Center for Cellular Therapy is being established at the University of Chicago Medicine to accelerate research in hard-to-treat cancers.Read more
UC San Diego bioengineers have developed a control system that could make CAR T-cell therapy safer and more powerful when treating cancer. By programming CAR T cells to switch on when exposed to blue light, the researchers controlled the cells to destroy skin tumors in mice without harming healthy tissue.Read more
Below are summaries of recent Fred Hutch research findings with links for additional background and media contacts.Read more
The 61st American Society of Hematology Annual Meeting and Exposition will take place Dec. 7–10 in Orlando, FloridaRead more
Three researchers at the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA have received awards totaling more than $18 million from the California Institute for Regenerative Medicine, the state’s stem cell agency.Read more
The prostate cancer program at the UCLA Jonsson Comprehensive Cancer Center and UCLA Health has been awarded an $8.7 million Specialized Program of Research Excellence, or SPORE, grant from the National Cancer Institute.Read more